Buspirone — BuSpar — is the non-benzodiazepine, non-controlled anxiolytic. The mechanism is entirely different from BZDs: buspirone is a 5-HT1A partial agonist with no direct effect on GABA-A. The clinical character is correspondingly different. No sedation. No cognitive impairment. No dependence. No abuse liability. No controlled-substance scheduling. The trade-offs are slow onset and modest effect size.
- Class
- Non-benzodiazepine anxiolytic (5-HT1A partial agonist)
- Mechanism
- 5-HT1A partial agonist (presynaptic autoreceptor and postsynaptic effects modulate serotonin signaling). No GABA-A activity.
- Typical dose
- 15-60 mg/day in 2-3 divided doses
- Half-life
- ~2-3 hours
- FDA indications
- Generalized anxiety disorder
- Key adverse effects
- Dizziness, headache, nausea, no sedation, no cognitive impairment, no dependence, no abuse liability
Useful when: chronic anxiety, no need for rapid effect, want non-controlled option, history of substance use disorder. Limitations: slow onset (2-4 weeks for full effect), not useful for acute anxiety/panic, less broadly anxiolytic than SSRIs/SNRIs.
Buspirone takes 2-4 weeks to reach full anxiolytic effect — comparable to SSRIs. It is useless for acute anxiety or panic. The patient who walks in with a panic attack needs lorazepam, not buspirone. The patient with chronic generalized anxiety who has weeks to build to therapeutic effect can benefit from buspirone over months.
Buspirone is a non-benzodiazepine anxiolytic — a serotonergic agent with a slow-onset, dependence-free profile that is its defining contrast to the benzodiazepines.
Mechanism note: Buspirone trades the benzodiazepine's speed for safety — slow onset and no acute relief, but no dependence, sedation, or abuse potential. The expectation-setting conversation determines whether patients stay on it.
The effect size is real but modest — generally less robust than SSRIs or SNRIs for anxiety. Buspirone is rarely curative; it is often part of a broader anxiety treatment regimen.
The dosing is TID, which is an adherence challenge. Start 5 mg TID, titrate to 15-30 mg TID over weeks. The frequent dosing is the major practical limitation.
The clinical niche is specific. Substance use history: buspirone is non-controlled, has no abuse liability, no cross-tolerance with alcohol or other substances. For the patient with alcohol or sedative-hypnotic use disorder who needs anxiolytic treatment, buspirone is often the right starting point. Augmentation: buspirone is one of the older established augmentation strategies for partial SSRI response in depression and anxiety; adds 5-HT1A activation without overlapping serotonergic mechanism.
For acute or moderate-to-severe anxiety, buspirone is rarely first-line. For chronic anxiety in patients where BZDs are inappropriate and where slow onset is acceptable, buspirone earns its place.